BioInvent International AB

Equities

BINV

SE0015244520

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:45 2024-05-24 EDT			5-day change	1st Jan Change
32.95 ^SEK	+3.62%		+10.02%	+73.79%

05-23	BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	CI
05-23	BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	CI

BioInvent International AB Appoints Nomination Committee for the Annual General Meeting 2022

November 25, 2021 at 02:30 am

The following representatives of BioInvent International AB?s shareholders will be members of the nomination committee for the Annual General Meeting 2022: Laura Feinleib, appointed by Redmile Group, LLC; Erik Esveld, appointed by van Herk Investments B.V; Vincent Ossipow, appointed by Omega Funds, LP; Leonard Kruimer, Chairman of the Board.

Latest news about BioInvent International AB

BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors	05-23	CI
BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024	05-23	CI
Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL	05-14	CI
Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member	05-03	CI
BioInvent Announces Evaluating Attana Technology	04-30	CI
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	04-03	MT
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024	02-22
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
BioInvent International AB Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607	12-05	CI
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910	12-05	CI
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent	11-03	CI
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910	23-10-31	CI
Transcript : BioInvent International AB, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
BioInvent International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
BioInvent International Enrolls First Patient for Phase 2a Trial of Cancer Therapy	23-09-22	MT
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-09-22	CI
BioInvent International AB(OM:BINV) dropped from S&P Global BMI Index	23-09-18	CI
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors	23-09-08	CI
BioInvent International To Receive $1 Million Milestone Payment in Exelixis Research Deal	23-09-07	MT
Bioinvent International AB Achieves Research Milestone Event in Its Exclusive Option and License Agreement with Exelixis, Inc	23-09-07	CI
BioInvent International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI

Chart BioInvent International AB

Duration

Period

More charts

Company Profile

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract Number: 2641

More about the company

Income Statement Evolution

More financial data

Ratings for BioInvent International AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

32.95 SEK

Average target price

83 SEK

Spread / Average Target

+151.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOINVENT INTERNATIONAL AB	+73.79%	204M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs